The global scleroderma diagnostics and therapeutics market size was estimated to be USD 2.54 billion in 2023 and is expected to reach USD 6.41 billion by 2034 with a CAGR of 8.76% during the forecast period 2024-2034. The increasing prevalence of scleroderma, advancements in diagnostic technologies, biotechnological and pharmaceutical innovations, collaborations and partnerships, awareness and early diagnosis campaigns, and government initiatives and funding will drive the market growth.
Global scleroderma case reports are increasing, which adds to the growing need for treatments and diagnostics. New treatment approaches and diagnostic techniques are being developed in the realm of autoimmune disorders, such as scleroderma, thanks to ongoing research and development efforts. Accurate diagnosis and early detection are improved by ongoing advancements in diagnostic technologies, including genetic testing, imaging methods, and biomarker discovery. For instance, Roche reported good Phase 2b findings in November 2023 for the treatment of early diffuse cutaneous systemic sclerosis (dcSSc) using Actemra (tocilizumab) in conjunction with methotrexate.
By disease type, the systemic scleroderma segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing prevalence of this form of the disease, advancements in early detection technologies, and the development of targeted therapeutics that address the complex pathophysiology associated with systemic scleroderma. For instance, in October 2023, Boehringer Ingelheim established the Boehringer Ingelheim Scleroderma Clinical Research Center in collaboration with Cedars-Sinai Medical Center. Additionally, the localized scleroderma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on early diagnosis and intervention, advancements in localized treatment modalities, and a growing awareness of the disease among healthcare professionals and the general public.
By drugs, the immunosuppressive agents segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of these medications for managing autoimmune responses and inflammation associated with scleroderma. For instance, in September 2023, the FDA approved Bristol-Myers Squibb's Ocrevus (ocrelizumab) to treat anti-MAG positive primary progressive multiple sclerosis (PPMS), a condition that may also help certain people with sickle cell disease. Additionally, the endothelin receptor antagonists (ERAs) and Phosphodiesterase-5 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their effectiveness in managing vascular complications associated with scleroderma.
By diagnosis, the imaging techniques segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of advanced diagnostic technologies such as high-resolution ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans. For instance, AbbVie presented findings at the American College of Rheumatology (ACR) meeting in December 2023 that suggested Upadacitinib could be useful in reducing skin stiffening in individuals with systemic sclerosis. Additionally, the blood tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on precision diagnostics, advancements in biomarker identification, and the growing recognition of blood-based assays as reliable tools for early detection and monitoring of scleroderma.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the centralized and comprehensive healthcare services offered by hospitals, making them primary centers for the diagnosis, treatment, and management of scleroderma patients. For instance, Pfizer and the Scleroderma Research Foundation established a partnership in November 2023 to establish a patient registry aimed at advancing clinical trials and research related to SSc. Additionally, the home healthcare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient-centered care, advancements in telemedicine and remote monitoring technologies, and a growing preference for managing chronic conditions, such as scleroderma, in the comfort of patients' homes.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of scleroderma, robust research and development activities, and a high level of awareness among both healthcare professionals and the general population. For instance, in July 2023, Boehringer Ingelheim released the findings of a research showing that nintedanib may help people with sickle cell lung disease. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of scleroderma, a rising prevalence of autoimmune diseases, and a growing focus on enhancing healthcare infrastructure.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Global scleroderma case reports are increasing, which adds to the growing need for treatments and diagnostics. New treatment approaches and diagnostic techniques are being developed in the realm of autoimmune disorders, such as scleroderma, thanks to ongoing research and development efforts. Accurate diagnosis and early detection are improved by ongoing advancements in diagnostic technologies, including genetic testing, imaging methods, and biomarker discovery. For instance, Roche reported good Phase 2b findings in November 2023 for the treatment of early diffuse cutaneous systemic sclerosis (dcSSc) using Actemra (tocilizumab) in conjunction with methotrexate.
By disease type, the systemic scleroderma segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing prevalence of this form of the disease, advancements in early detection technologies, and the development of targeted therapeutics that address the complex pathophysiology associated with systemic scleroderma. For instance, in October 2023, Boehringer Ingelheim established the Boehringer Ingelheim Scleroderma Clinical Research Center in collaboration with Cedars-Sinai Medical Center. Additionally, the localized scleroderma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on early diagnosis and intervention, advancements in localized treatment modalities, and a growing awareness of the disease among healthcare professionals and the general public.
By drugs, the immunosuppressive agents segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of these medications for managing autoimmune responses and inflammation associated with scleroderma. For instance, in September 2023, the FDA approved Bristol-Myers Squibb's Ocrevus (ocrelizumab) to treat anti-MAG positive primary progressive multiple sclerosis (PPMS), a condition that may also help certain people with sickle cell disease. Additionally, the endothelin receptor antagonists (ERAs) and Phosphodiesterase-5 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their effectiveness in managing vascular complications associated with scleroderma.
By diagnosis, the imaging techniques segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of advanced diagnostic technologies such as high-resolution ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans. For instance, AbbVie presented findings at the American College of Rheumatology (ACR) meeting in December 2023 that suggested Upadacitinib could be useful in reducing skin stiffening in individuals with systemic sclerosis. Additionally, the blood tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on precision diagnostics, advancements in biomarker identification, and the growing recognition of blood-based assays as reliable tools for early detection and monitoring of scleroderma.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the centralized and comprehensive healthcare services offered by hospitals, making them primary centers for the diagnosis, treatment, and management of scleroderma patients. For instance, Pfizer and the Scleroderma Research Foundation established a partnership in November 2023 to establish a patient registry aimed at advancing clinical trials and research related to SSc. Additionally, the home healthcare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient-centered care, advancements in telemedicine and remote monitoring technologies, and a growing preference for managing chronic conditions, such as scleroderma, in the comfort of patients' homes.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of scleroderma, robust research and development activities, and a high level of awareness among both healthcare professionals and the general population. For instance, in July 2023, Boehringer Ingelheim released the findings of a research showing that nintedanib may help people with sickle cell lung disease. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of scleroderma, a rising prevalence of autoimmune diseases, and a growing focus on enhancing healthcare infrastructure.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Disease Type, Drugs, Diagnosis, End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Scleroderma Diagnostics and Therapeutics Market Report 2023 - 2034
Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)
- Localized Scleroderma
- Systemic Scleroderma
Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Drugs 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- Immunosuppressive Agents
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- PDE-5 Inhibitors
- Chelating Agents
- Prostacyclin Analogues
- Others
Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)
- Antibodies Tests/Blood Tests
- Capillaroscopy
- Cardiac Diagnosis
- Gastrointestinal Diagnosis
- Imaging (CT and MRI)
- Pulmonary Diagnosis
- Skin Viscoelasticity
- General
Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Ambulatory Surgery Centers
- Home Healthcare
- Research Laboratories
Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Scleroderma Diagnostics and Therapeutics Market: Disease Type Estimates & Trend Analysis
8. Scleroderma Diagnostics and Therapeutics Market: Drugs Estimates & Trend Analysis
9. Scleroderma Diagnostics and Therapeutics Market: Diagnosis Estimates & Trend Analysis
10. Scleroderma Diagnostics and Therapeutics Market: End-User Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Scleroderma Diagnostics and Therapeutics Market
13. Europe Global Scleroderma Diagnostics and Therapeutics Market
14. Asia Pacific Global Scleroderma Diagnostics and Therapeutics Market
15. Latin America Global Scleroderma Diagnostics and Therapeutics Market
16. MEA Global Scleroderma Diagnostics and Therapeutics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson Services Inc.
- Eli Lilly and Company
- Pfizer Inc.
- Novartis International AG
- Sanofi
- Abbvie Inc.
- Genentech Inc. (a member of the Roche Group)
- Actelion Pharmaceuticals Ltd. (a Janssen Pharmaceutical Company of Johnson & Johnson)
- Celgene Corporation (acquired by Bristol Myers Squibb)
- Mylan N.V.
- Biogen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.54 Billion |
| Forecasted Market Value ( USD | $ 6.41 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
